Analyst Price Targets — OBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 9:14 am | Matt Miksic | Barclays | $13.00 | $4.06 | TheFly | Orchestra BioMed price target raised to $13 from $12 at Barclays |
| January 9, 2026 12:21 pm | Matt Miksic | Barclays | $12.00 | $4.84 | TheFly | Orchestra BioMed price target raised to $12 from $11 at Barclays |
| March 20, 2025 9:42 am | Marie Thibault | BTIG | $12.00 | $4.35 | TheFly | Orchestra BioMed initiated with a Buy at BTIG |
Latest News for OBIO
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution,…
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options…
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will be participating in the Jefferies Global Healthcare Conference.
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.49 per share a year ago.
NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2026, and provided a business update highlighting momentum across the Company's pivotal-stage…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OBIO.
U.S. House Trading
No House trades found for OBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.